MVA85A
MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG.[1] Phase I clinical trials have been completed[2] and phase II clinical trials are currently underway in South Africa.[3] As of late 2010, those trials, while promising, were not expected to be finished until late 2015, with efficacy trials running in parallel from 2009 to 2019.[4] By contrast, results released in February 2013 were described as "disappointing", showing only a statistically insignificant prevention rate in infants.[5] Results published in 2015 bring the further doubt on the efficacy of the vaccine.[6]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
